Standardized Serum Mixture for Allergen Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining allergen potency in allergen preparations are non-standardized, leading to inconsistencies in product quality and efficacy due to variations in raw material quality, extraction processes, and individual patient immune reactions, making it difficult to compare products across different manufacturers and batches.
Innovation Solution
A method involving the preparation of a standardized serum mixture by selecting multiple serum samples from moderately hypersensitive patients, determining the relative content of allergen-sIgE, calculating mean values and deviations, and removing extreme values to create a stable serum mixture for consistent allergen potency assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If W/V unit is used to indicate allergen concentration, then the measurement is simple, but it cannot accurately reflect the titer or potency of the allergen
Solution Approach 1:
The patent transitions from physical/chemical parameters (W/V concentration, protein content) to biological parameters (titer, potency measured by BU or BAU) by using standardized serum mixtures containing IgE antibodies that react specifically with allergens, thereby changing the measurement parameter from simple concentration to biologically active potency
2Manufacturing precision
If PNU unit is used to normalize protein content, then the protein quantity is standardized, but it cannot evaluate the gross potency of allergen product
Solution Approach 1:
The patent introduces standardized serum mixture containing IgE antibodies as an intermediary substance that specifically binds to allergens. This intermediary enables the measurement of biological potency by detecting the binding reaction between IgE and allergen, rather than directly measuring protein content
3Measurement precision
If BU or BAU is used to reflect gross potency titer, then the allergen potency is accurately measured, but the method depends on patient availability and selection criteria
Solution Approach 1:
The patent creates a standardized serum mixture that copies and consolidates the immune response characteristics of multiple patients into a single reference material. This copy eliminates the need for repeated patient recruitment and selection while preserving the biological measurement capability
4Ease of operation
If in vitro IgE detection methods are used, then the detection can be performed without patients, but the results are not reproducible due to variable serum pool composition
Solution Approach 1:
The patent standardizes the serum pool by selecting sera from patients with moderate hypersensitivity (skin test reaction grade ++ to +++), determining sIgE content, and mixing after removing extreme values. This parameter control transforms variable serum pools into standardized reference materials with consistent composition
Solution Approach 2:
The patent implements a feedback mechanism by measuring sIgE content in each serum sample, comparing against the mean value, and removing samples with deviations greater than 30%. This feedback loop ensures the final serum mixture has stable and reproducible composition
Data Source
AI summary
A method for preparing standardized serum mixture for determining allergen potency which comprises: 1) providing multiple serum samples from patients moderately hypersensitive to said allergen; 2) determining the relative content of sIgE against said allergen in each serum sample, obtaining the mean value of the relative content of sIgE of said multiple serum samples, and obtaining deviation value of the relative content of sIgE of each serum with respect to said mean value; 3) removing at least 5% of serum samples that have the largest and smallest deviation values respectively, and mixing the residual sera in the same volume. A serum mixture prepared by the method as well as the use of such serum mixture are also described.